RIPK1 is being investigated clinically as an important pharmacological target for the treatment of a variety of human diseases characterized by inflammation and degeneration.5 In particular, RIPK1-dependent programmed cell death, including RDA and necroptosis, and inflammation has emerged as potential important mechanisms in promoting the progressive cell death of motor neurons in the pathogenesis of ALS.6,18,19 A RIPK1 inhibitor has been advanced into Phase II human clinical trials for the treatment of ALS. Here, RIPK1 is linked to amyotrophic lateral sclerosis.